Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Blerim Mujaj

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Transplantation Direct|May 26, 2018
Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept StudyQi-Fang Huang, Sander Trenson, Zhen-Yu Zhang, et al.
European Journal of Heart Failure|January 18, 2020
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trialPierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 6, 2021
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trialJoão Pedro Ferreira, Timothy Collier, Andrew L Clark, et al.
JACC. Heart Failure|February 7, 2021
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HFJoão Pedro Ferreira, Job Verdonschot, Ping Wang, et al.
European Heart Journal|November 20, 2020
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trialJohn G F Cleland, João Pedro Ferreira, Beatrice Mariottoni, et al.
Journal of Hypertension|December 10, 2024
Racial and regional disparities in the risk of noncommunicable disease between sub-Saharan black and European white patientsYu-Ling Yu, De-Wei An, Babangida S Chori, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Transplantation Direct|May 26, 2018
Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept StudyQi-Fang Huang, Sander Trenson, Zhen-Yu Zhang, et al.
European Journal of Heart Failure|January 18, 2020
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trialPierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 6, 2021
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trialJoão Pedro Ferreira, Timothy Collier, Andrew L Clark, et al.
JACC. Heart Failure|February 7, 2021
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HFJoão Pedro Ferreira, Job Verdonschot, Ping Wang, et al.
European Heart Journal|November 20, 2020
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trialJohn G F Cleland, João Pedro Ferreira, Beatrice Mariottoni, et al.
Journal of Hypertension|December 10, 2024
Racial and regional disparities in the risk of noncommunicable disease between sub-Saharan black and European white patientsYu-Ling Yu, De-Wei An, Babangida S Chori, et al.
Pageof 4